**09-J3000-39**

**Original Effective Date: 07/15/19**

**Reviewed: 09/09/26**

**Revised: 10/01/26**

# Subject: Step Therapy Requirements for Medicare Outpatient (Part B) Medications

**THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO MEDICARE ADVATANGE LINES OF BUSINESS ONLY.**

Description | Position Statement | Billing/Coding | Reimbursement | Related Guidelines | References | Updates

## DESCRIPTION:

The Centers for Medicare and Medicaid Services (CMS) has authorized Medicare Advantage (MA) plans to use step therapy for Part B drugs as part of a patient-centered care coordination program. Step therapy may include a Part B drug before Part B drug and Part D drug before Part B drug. Existing drug therapy must be grandfathered in; therefore, the step therapy program applies to new starts only. Medicare Advantage plans are permitted to require trial/failure of drugs supported only by off-label indication if well supported in accordance with CMS-approved compendia. Beneficiaries must also have the opportunity to participate in drug management care coordination activities, including at minimum: interactive medication review and associated consultations for enrollees to discuss all current medications and perform medication reconciliation and implementation medication adherence strategies to help enrollees with their medication regimen.

## POSITION STATEMENT:

Step therapy will be required, and **the definition of medical necessity met**, for the medications listed in the Table below provided **ALL** of the following are met (“1” to “4”):

1. The requested product meets the definition of a Medicare outpatient (Part B) drug; **AND**
2. The proposed use of the requested product has been determined to be a medically accepted indication; **AND**
3. The proposed use of the preferred alternative product has been determined to be a medically accepted indication; **AND**
4. The dose, frequency, and duration of use may not exceed the safety and efficacy data supporting the medically accepted indication

For Non-Preferred Drugs:

5. If requested drug is non-preferred, product specific criteria is met (where applicable)
    - **ONE** of the following:
        - Adequate trial of preferred alternative product **OR**
        - Contraindication to preferred alternative product **OR**
        - Continuing therapy of non-preferred product (within 365 days)

## Anti-Inflammatory Agents

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Injectable betamethasone<br>Injectable methylprednisolone<br>Injectable dexamethasone<br>Injectable hydrocortisone<br>Injectable triamcinolone | J0702<br>J1010<br>J1100<br>J1720<br>J2919<br>J3301<br>J3303 | Acthar HP<br>Cortrophin | J0801<br>J0802 |
| Injectable triamcinolone (Kenalog) | J3301 | Zilretta | J3304 |

## Asthma Therapy

| Preferred Product(s) | | Non-preferred Product (1) | | Non-Preferred Product (2)ж | |
|---|---|---|---|---|---|
| Fasenra<br>Nucala | J0517<br>J2182 | Cinqair | J2786 | жExdensur | J2361 |
| ж For Exdensur requires trial of preferred product Fasenra or Nucala AND Cinqair. | | | | | |

## Autoimmune Therapy

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Cosentyx SC* | C9399<br>J3590 | Cosentyx IV | J3247 |
| Tyenne<br>Avtozma | Q5135<br>Q5156 | Actemra<br>Tofidence | J3262<br>Q5133 |
| Inflectra<br>Infliximab (unbranded)<br>Remicade<br>Renflexis | Q5103<br>J1745<br>J1745<br>Q5104 | Zymfentra<br>Avsola | J1748<br>Q5121 |
| Inflectra<br>Infliximab (unbranded)<br>Remicade<br>Renflexis<br>Simponi Aria | Q5103<br>J1745<br>J1745<br>Q5104<br>J1602 | Orencia IV | J0129 |
| Pyzchiva<br>Steqeyma | Q9997<br>Q5099 | Stelara IV<br>Imuldosa<br>Otulfi<br>Selarsdi<br>Starjemza<br>Wezlana<br>Yesintek | J3358<br>Q5098<br>Q9999<br>Q9998<br>Q5164<br>Q5138<br>Q5100 |
| *Covered under Part D benefit (pre-authorization may apply) | | | |

## Bone Remodeling Agents

| Preferred Product(s) | | Non-preferred Product (1) | | Non-preferred Product (2) * | |
|---|---|---|---|---|---|
| Zoledronic acid | J3489 | Enoby<br>Stoboclo<br>Bildyos | Q5167<br>Q5157<br>Q5162 | *Prolia<br>*Evenity<br>*Conexxence<br>Ospomyv<br>Bosaya<br>Jubbonti<br>Osvyrti<br>Ponlimsi | J0897<br>J3111<br>Q5158<br>Q5159<br>Q5161<br>Q5136<br>Q5166<br>C9399, J3590 |
| *For Prolia, Evenity, Conexxence, Ospomyv, Bosaya or Enoby requires trial of preferred product Zoledronic acid **AND** one of the following: Jubbonti, Stoboclo or Bildyos. | | | | | |

## Cancer and Supportive Therapy

| Preferred Product(s) | | Non-preferred Product(s) | |
|---|---|---|---|
| granisetron<br>ondansetron<br>palonosetron | J1626<br>J2405<br>J2469 | Sustol (for all indications)<br>Posfrea | J1627<br>J2468 |
| Fosaprepitant | J1453 | Focinvez<br>Cinvanti | J1434<br>J0185 |
| Leucovorin | J0640,<br>J0643 | Fusilev<br>Khapzory<br>Vykoura<br>Leucovorin (avyxa) | J0641<br>J0642<br>J3490,<br>C9310<br>J0644 |
| Mvasi<br>Zirabev | Q5107<br>Q5118 | Avastin (for oncology diagnosis only)<br>Alymsys<br>Vegzelma<br>Avzivi<br>Jobevne | J9035<br>Q5126<br>Q5126<br>Q5129<br>J3590<br>Q5160 |
| Kanjinti<br>Ogivri<br>Trazimera | Q5117<br>Q5114<br>Q5116 | Herceptin<br>Herceptin Hylecta<br>Hercessi<br>Herzuma<br>Ontruzant | J9355<br>J9356<br>Q5146<br>Q5113<br>Q5112 |
| Belrapzo<br>Bendeka<br>Treanda | J9036<br>J9034<br>J9033 | Vivimusta | J9056 |
| Camptosar<br>Irinotecan | J9206 | Onivyde | J9205 |
| Pemetrexed (Alimta) | J9305 | Axtle | J9292 |
| Pemetrexed (teva) | J9314 | Pemfexy | J9304 |
| Pemetrexed (hospira) | J9294 | Pemrydi RTU | J9324 |
| Pemetrexed (accord) | J9296 | | |
| Pemetrexed (sandoz) | J9297 | | |

| | | | |
|---|---|---|---|
| Pemetrexed ditromethamine | J9323 | | |
| Gemcitabine IV (accord)<br>Gemcitabine IV | J9196<br>J9201 | Avgemsi | J9184 |
| Bortezomib<br>Bortezomib (hospira)<br>Bortezomib (maia) | J9041<br>J9049<br>J9051 | Boruzu | J9054 |
| Carboplatin | J9045 | Kyxata | J9278 |
| Docetaxel<br>Docetaxel (hospira) | J9171<br>J9232 | Docivyx<br>Beizray | J9172<br>J9174 |
| Thiotepa, Tepadina | J9342 | Tepylute | J9341 |
| Truxima<br>Ruxience<br>Riabni | Q5115<br>Q5119<br>Q5123 | Rituxan<br>Rituxan Hycela (for oncology diagnosis only) | J9312<br>J9310<br>J9311 |
| Note: Step Therapy also applies for non-cancer indications aligned with CMS coverage and Compendia supported indications. | | | |

| Preferred Product(s) | | Indication | Non-preferred Product | |
|---|---|---|---|---|
| Bortezomib | J9041<br>J9049<br>J9051 | Primary therapy for newly diagnosed and previously untreated multiple myeloma (MM)<br><br>Maintenance therapy for MM<br><br>POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome | Kyprolis+ | J9047 |
| + Note: Step Therapy applies for indications listed; ST does not apply for other Compendia supported indications not listed. | | | | |

| **Preferred Product(s)** | | **Non-preferred Product (1)** | | **Non-Preferred Product (2)*** | |
|---|---|---|---|---|---|
| Zoledronic acid | J3489 | Xtrenbo<br>Osenvelt<br>Bilprevda | Q5167<br>Q5157<br>Q5162 | *Xgeva<br>*Bomyntra<br>Xbryk<br>Aukelso<br>Wyost<br>Jubereq<br>Oziltus<br>Boncresa | J0897<br>Q5158<br>Q5159<br>Q5161<br>Q5136<br>Q5166<br>Q5165<br>Q5171 |
| *For Xgeva, Bomyntra, Xbryk, Aukelso or Xtrenbo requires trial of preferred product Zoledronic acid AND one of the following: Wyost, Osenvelt or Bilprevda. | | | | | |

## Cardiovascular/Cholesterol Lowering Agents

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Repatha* | J3590 | Leqvio | J1306 |
| Praluent* | C9399 | Evkeeza | J1305 |
| *Covered under Part D benefit (pre-authorization may apply) | | | |

## Colony Stimulating Factors

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Fulphila<br>Udenyca<br>Fylnetra | Q5108<br>Q5111<br>Q5130 | Neulasta<br>Rolvedon<br>Stimufend<br>Ryzneuta<br>Nypozi<br>Ziextenzo<br>Nyvepria | J2506<br>J1449<br>Q5127<br>J9361<br>Q5148<br>Q5120<br>Q5122 |
| Granix<br>Zarxio<br>Nivestym | J1447<br>Q5101<br>Q5110 | Neupogen<br>Releuko<br>Leukine<br>Filkri | J1442<br>Q5125<br>J2820<br>Q5172 |

## Complement Inhibitors

| Preferred Product(s) | | Indication | Non-preferred Product | |
|---|---|---|---|---|
| Ultomiris<br>Vyvgart<br>Vyvgart Hytrulo+<br>Rystiggo<br>Epysqli<br>Uplizna | J1303<br>J9332<br>J9334<br>J9333<br>Q5151<br>J1823 | Myasthenia gravis (gMG) | Soliris<br>PiaSky<br>Bkemv<br>Imaavy^ | J1300,J1299<br>J1307<br>Q5152<br>J9256 |
| Empaveli<br>Ultomiris<br>Epysqli | C9399<br>J3490<br>J1303<br>Q5151 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | | |
| Ultomiris<br>Epysqli | J1303<br>Q5151 | Hemolytic uremic syndrome, atypical (aHUS) | | |
| Enspryng<br>Uplizna<br>Ultomiris | C9399<br>J1823<br>J1303 | Neuromyelitis optica spectrum disorder (NMOSD) | | |

*ST does not apply for other orphan indications – only medical necessity criteria for **Soliris** as per CMS guidance.

*Other orphan indications: dermatomyositis, shiga-toxin producing E. coli HUS, idiopathic membranous glomerular nephropathy, prevention of delayed graft rejection in renal transplant

+Vyvgart Hytrulo is non-preferred for CIDP indication.

^Imaavy is currently indicated for Myasthenia gravis (gMG).

## Gout Agents

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Allopurinol* | | Krystexxa | J2507 |
| Febuxostat* | | | |
| *Covered under Part D benefit (pre-authorization may apply) | | | |

## Hemophilia A Agents

| Preferred Product(s) | | Non-preferred Product (1) | | Non-Preferred Product (2) | |
|---|---|---|---|---|---|
| Advate | J7192 | Alhemo | J7173 | Qfitlia | J7174 |
| Adynovate | J7207 | Altuviiio | J7214 | Hympavzi | J7172 |
| Afstyla | J7210 | Hemlibra | J7170 | | |
| Eloctate | J7205 | | | | |
| Esperoct | J7204 | | | | |
| Hemofil M | J7190 | | | | |
| Humate P | J7187 | | | | |
| Jivi | J7208 | | | | |
| Koate-DVI | J7190 | | | | |
| Kogenate FS | J7192 | | | | |
| Kovaltry | J7211 | | | | |
| NovoEight | J7182 | | | | |
| Recombinate | J7192 | | | | |
| Xyntha | J7185 | | | | |
| For Qfitlia or Hympavzi, requires trial of ONE preferred product: Advate, Adynovate, Afstyla, Eloctate, Esperoct, Hemofil M, Humate P, Jivi, Koate-DVI, Kogenate FS, Kovaltry, NovoEight, Recombinate, or Xyntha AND one of the following: Alhemo, Altuviiio or Hemlibra. | | | | | |

## Immune Globulins

| **Preferred Product(s)** | | | **Non-preferred Product** | |
|---|---|---|---|---|
| IVIG | Gammagard liquid | J1569 | Alyglo | J1599 |
| | Gammaked' Gamunex-C | J1561 | Asceniv | J1554 |
| | Privigen | J1459 | Bivigam | J1556 |
| | Octagam | J1568 | Gammagard S/D | J1566 |
| | | | Panzyga | J1576 |
| | | | Yimmugo | J3590 |
| | | | Qivigy | J1577 |
| SCIG | Cutaquig | J1551 | Cuvitru | J1555 |
| | Hizentra | J1559 | Xembify | J1558 |
| | HyQvia | J1575 | | |

## Immune Globulin Antibody Agents

| Preferred Product(s) | | Indication | Non-preferred Product | |
|---|---|---|---|---|
| Gammaked<br>Gamunex | J1561 | Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | Vyvgart<br>Hytrulo | J9334 |
| Privigen | J1459 | | | |
| Hizentra | J1559 | | | |
| Note: Other IVIG products not listed here, but with a recognized medical indication for CIDP, may also be applicable. | | | | |

## Iron Supplementation Agents

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Feraheme<br>Ferumoxytol | Q0138<br>Q0139 | Injectafer | J1439 |
| Ferrlecit<br>Sodium ferric gluconate | J2916 | Monoferric | J1437 |
| Infed | J1750 | | |
| Triferic | J1443<br>J1444<br>J1445 | | |
| Venofer | J1756 | | |

## Ophthalmic Agents

| Preferred Product(s) | | Non-preferred Product (1) | | Non-preferred Product (2)* | |
|---|---|---|---|---|---|
| Bevacizumab | J3490<br>C9257 | Byooviz<br>Cimerli<br>Eylea<br>Eylea HD<br>Lucentis<br>Vabysmo<br>Visudyne<br>Pavblu<br>Enzeevu<br>Ahzantive<br>Opuviz<br>Yesafili<br>Eydenzelt<br>Nufymco | Q5124<br>Q5128<br>J0178<br>J0177<br>J2778<br>J2777<br>J3396<br>Q5147<br>Q5149<br>Q5150<br>Q5153<br>Q5155<br>Q5170<br>Q5168 | Beovu<br>Susvimo | J0179<br>J2779 |
| *For Beovu or Susvimo, require trial of preferred product bevacizumab AND one of the following: Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Vabysmo, Visudyne, Pavblu, Enzeevu, Ahzantive, Opuviz, Yesafili or Eydenzelt. | | | | | |

| Preferred Product(s) | | Non-preferred Product(s) | |
|---|---|---|---|
| Syfovre | J2781 | Izervay | J2782 |

## Systemic Lupus Erythematosus (SLE) Agents

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Benlysta (IV) | J0490 | Saphnelo* | J0491 |
| Benlysta (SC) | C9399<br>J3590 | - | - |
| *ST Exception: Saphnelo non-preferred status does not apply if member has history of serious depression, serious psychiatric disorders or is at risk for suicidal behavior. | | | |

## Viscosupplements

| Preferred Product(s) | | Non-preferred Product | |
|---|---|---|---|
| Synvisc/Synvisc One<br>Orthovisc | J7325<br>J7324 | Durolane<br>Euflexxa<br>Gel-One<br>Gelsyn-3<br>Genvisc-850<br>Hyalgan<br>Hymovis<br>Monovisc<br>Supartz<br>Supartz FX<br>Synojoynt<br>Triluron<br>Trivisc<br>Visco-3 | J7318<br>J7323<br>J7326<br>J7328<br>J7320<br>J7321<br>J7322<br>J7327<br>J7321<br>J7321<br>J7331<br>J7332<br>J7329<br>J7321 |

Note: Step therapy may only be applied to new prescriptions or administrations of Part B drugs for enrollees that are not actively receiving the affected medication.

LEC = low emetogenic chemotherapy, MinEC = minimal emetogenic chemotherapy

**Exceptions**

- Medicare Advantage Products: Medical necessity is determined using any applicable NCD or LCD and then Step therapy Requirements for Medicare Outpatient (Part B) Medications (09-J3000-39).
- Enrollees must be able to request an exception from the plan's step therapy requirement in order to access a Part B covered drug. The ability to request such an exception is consistent with current Part D rules involving exceptions related to the application of utilization management tools, such as step therapy requirements. 42 CFR § 423.578(b)
- CMS considers plan decisions involving requests for exceptions to be pre-service organization determinations because they involve an MA plan's refusal to provide or pay for services that the enrollee believes should be furnished or arranged by the MA plan. 42 CFR § 422.566(b)(3)
- As a result, exception requests are subject to applicable adjudication timeframes and notice requirements in 42 CFR §§ 422.568 and 422.572. Organization determination timeframes require that MA plans make determinations as expeditiously as the enrollee's health condition requires, but no later than 72 hours (24 hours for expedited requests) after the date the organization receives the request.

**Approval duration**: 1 year

## BILLING/CODING INFORMATION:

The following codes may be used to describe:

## HCPCS Coding

| | |
|---|---|
| C9142 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg |
| C9166 | Injection, secukinumab, intravenous, 1 mg |
| C9257 | Injection, bevacizumab, 0.25 mg |
| J0129 | Injection, abatacept, 10 mg |
| J0177 | Injection, aflibercept hd, 1 mg |
| J0178 | Injection, aflibercept, 1 mg |
| J0179 | Injection, brolucizumab-dbll, 1 mg |
| J0185 | Injection, aprepitant, 1 mg |
| J0490 | Injection, belimumab, 10 mg |
| J0491 | Injection, anifrolumab-fnia, 1 mg |
| J0517 | Injection, benralizumab, 1 mg |
| J0640 | Injection, leucovorin calcium, per 50 mg |
| J0641 | Injection, levoleucovorin calcium, 0.5 mg |
| J0642 | Injection, levoleucovorin, 0.5mg |
| J0643 | Injection, leucovorin calcium, not otherwise specified, 1 mg |
| J0644 | Injection, leucovorin calcium (avyxa), 1 mg |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
| J0801 | Injection, corticotropin (acthar gel), up to 40 units |
| J0802 | Injection, corticotropin (ani), up to 40 units |
| J0897 | Injection, denosumab, 1 mg |
| J1010 | Injection, methylprednisolone acetate, 1 mg |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg |
| J1299 | Injection, eculizumab, 2 mg |
| J1300 | Injection, eculizumab, 10 mg |
| J1303 | Injection, ravulizumab-cwvz, 10 mg |
| J1305 | Injection, evinacumab-dgnb, 5mg |
| J1306 | Injection, inclisiran, 1 mg |
| J1434 | Injection, fosaprepitant (focinvez), 1 mg |
| J1437 | Injection, ferric derisomaltose, 10 mg |
| J1439 | Injection, ferric carboxymaltose, 1 mg |
| J1443 | Injection, ferric pyrophosphate citrate solution (triferic), 0.1 mg of iron |
| J1444 | Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron |
| J1445 | Injection, ferric pyrophosphate citrate solution (Triferic ), 0.1 mg of iron |
| J1447 | Injection, tbo-filgrastim, 1 microgram |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg |
| J1459 | Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g liquid), 500 mg |
| J1551 | Injection, immune globulin (cutaquig), 100 mg |
| J1554 | Injection, immune globulin (asceniv), 500 mg |
| J1555 | Injection, immune globulin (Cuvitru), 100 mg |
| J1556 | Injection, immune globulin (Bivigam), 500 mg |
| J1558 | Injection, immune globulin (xembify), 100 mg |
| J1559 | Injection, immune globulin (Hizentra), 100 mg |
| J1561 | Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g. liquid), 500 mg |
| J1566 | Injection, immune globulin, intravenous, lyophilized (e.g powder), not otherwise specified, 500 mg (Only Carimune NF, Panglobulin NF and Gammagard S/D should be billed using this code) |
| J1568 | Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g. liquid), |

| | |
|---|---|
| | 500 mg |
| J1569 | Injection, immune globulin, (Gammagard liquid), non-lyophilized, (e.g. liquid), 500 mg |
| J1575 | Injection, immune globulin/hyaluronidase, (Hyqvia), 100 mg immune globulin |
| J1576 | Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg |
| J1577 | Injection, immune globulin (qivigy), 100 mg |
| J1599 | Injection, immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified, 500 mg |
| J1602 | Injection, golimumab, 1 mg, for intravenous use |
| J1626 | Injection, granisetron hydrochloride, 100 mcg |
| J1627 | Injection, granisetron, extended release, 0.1 mg |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg |
| J1748 | Injection, infliximab-dyyb (zymfentra), 10 mg |
| J1750 | Injection, iron dextran, 50 mg |
| J1756 | Injection, iron sucrose, 1 mg |
| J1823 | Injection, inebilizumab-cdon, 1 mg |
| J9171 | Injection, docetaxel, 1 mg |
| J2182 | Injection, mepolizumab, 1 mg |
| J2361 | Injection, depemokimab-ulaa, 1 mg |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg |
| J2468 | Injection, palonosetron hydrochloride (posfrea), 25 micrograms |
| J2469 | Injection, palonosetron HCl, 25 mcg |
| J2503 | Injection, pegaptanib sodium, 0.3 mg |
| J2506 | Injection, pegfilgrastim, 6 mg |
| J2507 | Injection, pegloticase, 1 mg |
| J2777 | Injection, faricimab-svoa, 0.1 mg |
| J2778 | Injection, ranibizumab, 0.1 mg |
| J2779 | Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg |
| J2782 | Injection, avacincaptad pegol, 0.1 mg |
| J2786 | Injection, reslizumab, 1 mg |
| J2820 | Injection, sargramostim (GM-CSF), 50 mcg |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg |
| J3111 | Injection, romosozumab-aqqg, 1 mg |
| J3247 | Injection, secukinumab, intraveneous, 1 mg |
| J3262 | Injection, tocilizumab, 1 mg |
| J3301 | Injection, triamcinolone acetonide, Not Otherwise Specified, per 10 mg |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended release, microsphere formulation, 1 mg |
| J9342 | Injection, thiotepa, not otherwise specified, 1 mg |
| J3358 | Ustekinumab, for intravenous injection, 1 mg |
| J3396 | Injection, verteporfin, 0.1 mg |
| J3489 | Injection, zoledronic acid, 1 mg |
| J7182 | Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU |
| J7185 | Injection, factor VIII (antihemophilic factor, recombinant) (Xyntha), per IU |
| J7187 | Injection, Von Willebrand factor complex (Humate-P), per IU, VWF:RCO |
| J7190 | Factor VIII (antihemophilic factor [human]) per IU |
| J7192 | Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified |
| J7204 | Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu |

| | |
|---|---|
| J7205 | Injection, factor VIII, Fc fusion protein (recombinant), per IU |
| J7207 | Injection, factor VIII, (antihemophilic factor, recombinant), pegylated, 1 IU |
| J7208 | Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u. |
| J7210 | Injection, factor VIII, (antihemophilic factor, recombinant), (Afstyla), 1 IU |
| J7211 | Injection, factor VIII, (antihemophilic factor, recombinant), (Kovaltry), 1 IU |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg |
| J7320 | Hyaluronan or derivative, Genvisc 850, for intra-articular injection, 1 mg |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection |
| J7322 | Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg |
| J7323 | Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose (20 mg/2 mL) |
| J7324 | Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose (30 mg/2 mL) |
| J7325 | Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg |
| J7326 | Hyaluronan or derivative, Gel-One, for intra-articular injection |
| J7327 | Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose |
| J7328 | Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg |
| J7331 | Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg |
| J7332 | Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg |
| J9033 | Injection, bendamustine HCL, 1 mg |
| J9034 | Injection, bendamustine HCl (Bendeka), 1 mg |
| J9035 | Injection, bevacizumab, 10mg |
| J9036 | Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg |
| J9041 | Injection, bortezomib, 0.1 mg |
| J9045 | Injection, carboplatin, 50 mg |
| J9047 | Injection, carfilzomib, 1 mg |
| J9049 | Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg |
| J9051 | Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg |
| J9054 | Injection, bortezomib (boruzu), 0.1 mg |
| J9056 | Injection, bendamustine hydrochloride (Vivimusta), 1 mg |
| J9172 | Injection, docetaxel (docivyx), 1 mg |
| J9174 | Injection, docetaxel (beizray), 1 mg |
| J9184 | Injection, gemcitabine hydrochloride (avyxa), 200 mg |
| J9196 | Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201 |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
| J9205 | Injection, irinotecan liposome, 1 mg |
| J9206 | Injection, irinotecan, 20 mg |
| J9232 | Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg |
| J9256 | Injection, nipocalimab-aahu, 3 mg |
| J9278 | Injection, carboplatin (avyxa), 1 mg |
| J9294 | Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg |
| J9296 | Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg |
| J9297 | Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg |
| J9311 | Injection, rituximab, 10mg and hyaluronidase |
| J9312 | Injection, rituximab, 10mg |
| J9314 | Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg |
| J9323 | Injection, pemetrexed ditromethamine, 10 mg |
| J9324 | Injection, pemetrexed (pemrydi rtu), 10 mg |
| J9332 | Injection, efgartigimod alfa-fcab, 2mg |
| J9333 | Injection, rozanolixizumab-noli, 1 mg |

| | |
|---|---|
| J9334 | Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc |
| J9355 | Injection, trastuzumab 10 mg |
| J9341 | Injection, thiotepa (tepylute), 1 mg |
| J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk |
| J9361 | Injection, Efbemalenograstim alfa-vuxw, 0.5 mg |
| J9041 | Injection, bortezomib, 0.1 mg |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use) |
| Q0139 | Injection, ferumoxytol for treatment of iron deficiency anemia, 1 mg (for ESRD on dialysis) |
| Q5098 | Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg |
| Q5099 | Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg |
| Q5100 | Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 microgram |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg |
| Q5104 | Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
| Q5108 | Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 microgram |
| Q5111 | Injection, Pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg |
| Q5113 | Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg |
| Q5114 | Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg |
| Q5115 | Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
| Q5120 | Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg |
| Q5122 | Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufendbiosimilar, 0.5 mg |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg |
| Q5133 | Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg |
| Q5135 | Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg |
| Q5138 | Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg |
| Q5146 | Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg |
| Q5147 | Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram |
| Q5149 | Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg |
| Q5150 | Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg |
| Q5151 | Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg |
| Q5152 | Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg |
| Q5153 | Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg |
| Q5155 | Injection, aflibercept-jbvf (yesafili),biosimilar, 1 mg |
| Q5156 | Injection, tocilizumab-anoh(avtozma), biosimilar, 1 mg |
| Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg |

| | |
|---|---|
| Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg |
| Q5159 | Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg |
| Q5161 | Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg |
| Q5165 | Injection, denosumab-mobz (oziltus), biosimilar, 1 mg |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg |
| Q5171 | Injection, denosumab-mobz (boncresa), biosimilar, 1 mg |
| Q5172 | Injection, filgrastim-laha (filkri), biosimilar, 1 microgram |
| Q9997 | Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg |
| Q9998 | Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg |
| Q9999 | Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg |

## ICD-10 Diagnosis Codes That Support Medical Necessity

| **Acthar, Cortrophin** | |
|---|---|
| A15.0 – A15.9 | Respiratory tuberculosis |
| A17.0 | Tuberculous meningitis |
| B02.39 | Other herpes zoster eye disease |
| B75 | Trichinellosis |
| C81.00 – C96.9 | Malignant neoplasm of lymphatic and hematopoietic tissue |
| D59.00 – D59.9 | Acquired hemolytic anemias |
| D61.01 | Constitutional (pure)red cel aplasia |
| D61.89 | Other aplastic anemias and other bone marrow failure syndromes |
| D69.59 | Other secondary thrombocytopenia |
| D86.0 – D86.9 | Sarcoidosis |
| E06.1 | Subacute thyroiditis |
| E83.52 | Hypercalcemia |
| G12.21 | Amyotrophic lateral sclerosis |
| G35 | Multiple sclerosis |
| H10.001 – H10.44 | Conjunctivitis |
| H16.001 – H16.299 | Keratitis |
| H20.00 – H20.9 | Iridocyclitis |
| H30.001 – H30.93 | Chorioretinal inflammations |
| H44.11 – H44.19 | Other endophthalmitis |
| H44.131 – H44.139 | Sympathetic uveitis |
| H46.00 – H46.9 | Optic neuritis |
| I100 – I02.9 | Acute rheumatic fever |
| J30.01 – J30.9 | Allergic rhinitis |
| J45.20 – J45.998 | Asthma |
| J63.2 | Berylliosis |
| J68.0 | Bronchitis and pneumonitis due to chemicals, gases, fumes and vapors |
| J69.0 – J69.8 | Pneumonitis due to inhalation of food or vomit |
| J82 | Pulmonary eosinophilia |
| K29.60 – K29.61 | Other gastritis |
| K50.00 – K50.919 | Chron’s disease |
| K51.00 – K51.919 | Ulcerative colitis |
| K52.21 – K52.29 | Allergic and dietary gastroenteritis and colitis |
| L10.0 – L10.9 | Pemphigus |
| L13.0 | Dermatitis herpetiformis |
| L21.8 – L21.9 | Seborrheic dermatosis |
| L24.0 – L24.9 | Irritant contact dermatitis |
| L27.0 – L27.9 | Dermatitis due to substances taken internally |
| L40.0 – L40.9 | Psoriasis |
| L50.0 – L50.9 | Urticaria |

| | |
|---|---|
| L51.1 | Stevens-Johnson syndrome |
| M05.00 – M14.89 | Inflammatory polyarthropathies |
| M10.00 – M10.09 | Idiopathic gout |
| M15.0 – M19.93 | Osteoarthritis |
| M32.0 – M32.9 | Systemic lupus erythematosus |
| M45.0 – M45.9 | Ankylosing spondylitis |
| M75.00 – M77.9 | Shoulder lesions |
| N04.0 – N04.9 | Nephrotic syndrome |
| T50.905 | Adverse effect of unspecified drugs, medicaments, and biological substances |
| T78.3 | Angioneurotic edema |
| T78.40 | Allergy, unspecified |
| T80.51 – T80.59 | Anaphylactic reaction due to serum |
| T80.61 – T80.69 | Other serum reaction |

| **Aloxi** | |
|---|---|
| R11.0 | Nausea |
| R11.10 | Vomiting, unspecified |
| R11.11 | Vomiting without nausea |
| R11.12 | Projectile vomiting |
| R11.2 | Nausea with vomiting, unspecified |
| T45.1X5A | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter |
| T45.1X5D | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter |
| T45.1X5S | Adverse effect of antineoplastic and immunosuppressive drugs, sequela |
| T45.95XA | Adverse effect of unspecified primarily systemic and hematological agent, initial encounter |
| T50.905A | Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter |
| T50.905S | Adverse effect of unspecified drugs, medicaments and biological substances, sequela |
| T66.xxxS | Radiation sickness, unspecified, sequela |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| Z51.12 | Encounter for antineoplastic chemotherapy |

| **Bendamustine HCL** | |
|---|---|
| B20 | Human immunodeficiency virus (HIV) disease |
| C81.00 – C81.09 | Nodular lymphocyte predominant Hodgkin lymphoma |
| C81.10 – C81.19 | Nodular sclerosis classical Hodgkin lymphoma |
| C81.20 – C81.29 | Mixed cellularity classical Hodgkin lymphoma |
| C81.30 – C81.39 | Lymphocyte depleted classical Hodgkin lymphoma |
| C81.40 – C81.49 | Lymphocyte-rich classical Hodgkin lymphoma |
| C81.70 – C81.79 | Other classical Hodgkin lymphoma |
| C81.90 – C81.99 | Hodgkin lymphoma, unspecified |
| C82.00 – C82.09 | Follicular lymphoma grade I |
| C82.10 – C82.19 | Follicular lymphoma grade II |
| C82.20 – C82.29 | Follicular lymphoma grade III, unspecified |
| C82.30 – C82.39 | Follicular lymphoma grade IIIa |
| C82.40 – C82.49 | Follicular lymphoma grade IIIb |
| C82.50 – C82.59 | Diffuse follicle center lymphoma |
| C82.60 – C82.69 | Cutaneous follicle center lymphoma |
| C82.80 – C82.89 | Other types of follicular lymphoma |
| C82.90 – C82.99 | Follicular lymphoma, unspecified |
| C83.00 – C83.09 | Small B-cell lymphoma |

| | |
|---|---|
| C83.10 – C83.19 | Mantle cell lymphoma |
| C83.30 – C83.39 | Diffuse large B-cell lymphoma |
| C83.50 – C83.59 | Lymphoblastic (diffuse) lymphoma |
| C83.80 – C83.89 | Other non-follicular lymphoma |
| C83.90 – C83.99 | Non-follicular (diffuse) lymphoma, unspecified |
| C84.00 – C84.09 | Mycosis fungoides |
| C84.40 – C84.49 | Peripheral T-cell lymphoma, not classified |
| C84.60 – C84.69 | Anaplastic large cell lymphoma, ALK-positive |
| C84.70 – C84.79 | Anaplastic large cell lymphoma, ALK-negative |
| C84.90 – C84.99 | Mature T/NK-cell lymphomas, unspecified |
| C84.Z0 – C84.Z9 | Other mature T/NK-cell lymphomas |
| C85.20 – C85.29 | Mediastinal (thymic) large B-cell lymphoma |
| C85.80 – C85.89 | Other specified types of non-Hodgkin lymphoma |
| C86.1 | Hepatosplenic T-cell lymphoma |
| C86.2 | Enteropathy-type (intestinal) T-cell lymphoma |
| C86.5 | Angioimmunoblastic T-cell lymphoma |
| C86.6 | Primary cutaneous CD30-positive T-cell proliferations |
| C88.0 | Waldenström macroglobulinemia |
| C88.4 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] |
| C88.8 | Other malignant immunoproliferative diseases |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| C90.10 | Plasma cell leukemia not having achieved remission |
| C90.12 | Plasma cell leukemia in relapse |
| C90.20 | Extramedullary plasmacytoma not having achieved remission |
| C90.22 | Extramedullary plasmacytoma in relapse |
| C90.30 | Solitary plasmacytoma not having achieved remission |
| C90.32 | Solitary plasmacytoma in relapse |
| C91.10 | Chronic lymphocytic leukemia of B-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of B-cell type in relapse |
| C91.50 | Adult T-cell lymphoma/leukemia (HTLV-1-associated), not having achieved remission |
| C91.52 | Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse |
| D47.Z1 | Post-transplant lymphoproliferative disorder (PTLD) |

| **Benlysta** | |
|---|---|
| M32.10-M32.9 | Systemic lupus erythematosus, organ or system involvement unspecified |

| **Cinqair** | |
|---|---|
| J82 | Pulmonary eosinophilia, not elsewhere classified |

| **Cinvanti** | |
|---|---|
| Rll.0 | Nausea |
| Rll.10 – Rll.12 | Vomiting, unspecified |
| Rll.2 | Nausea with vomiting, unspecified |
| T45.1XSA | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter |
| T45.1XSD | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter |

| | |
|---|---|
| T45.1XSS | Adverse effect of antineoplastic and immunosuppressive drugs, sequela |
| T45.95XA | Adverse effect of unspecified primarily systemic and hematological agent, initial encounter |
| TS0.905A | Adverse effect of unspecified drugs, medicaments and biological substances |
| ZSl.11 | Encounter for antineoplastic chemotherapy |
| ZSl.12 | Encounter for antineoplastic immunotherapy |

| **Cosentyx IV** | |
|---|---|
| L40.50 | Arthropathic psoriasis, unspecified |
| L40.51 | Distal interphalangeal psoriatic arthropathy |
| L40.52 | Psoriatic arthritis mutilans |
| L40.53 | Psoriatic spondylitis |
| L40.59 | Other psoriatic arthropathy |
| M45.0 – M45.9 | Ankylosing spondylitis |
| M45.A0 – M45.AB | Non-radiographic axial spondyloarthritis |

| Docivyx, Beizray | |
|---|---|
| C00.0 – C02.9 | Malignant neoplasm of lip, base of tongue and other and unspecified part of tongue |
| C03.0 – C03.9 | Malignant neoplasm of gum |
| C04.0 – C04.9 | Malignant neoplasm of floor of mouth |
| C05.0 – C06.9 | Malignant neoplasm of palate and other and unspecified parts of ought |
| C07 | Malignant neoplasm of parotid gland |
| C09.0 – Cl0.9 | Malignant neoplasm of tonsil and oropharynx |
| Cll.0 – Cll.9 | Malignant neoplasm of nasopharynx |
| C12 – C13.9 | Malignant neoplasm of pyriform sinus and hypopharynx |
| Cl4.0 – C14.8 | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx |
| ClS.3 – ClS.9 | Malignant neoplasm of esophagus |
| C16.0 – C16.9 | Malignant neoplasm of stomach |
| C26.9 | Malignant neoplasm of ill-defined sites within the digestive system |
| C31.0 – C31.1 | Malignant neoplasm of maxillary sinus and ethmoidal sinus |
| C32.0 – C32.9 | Malignant neoplasm of larynx |
| C33 – C34.92 | Malignant neoplasm of trachea and bronchus and lung |
| C40.00 – C44.09 | Malignant neoplasm of bone and articular cartilage of limbs |
| C41.0 – C41.9 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites |
| C44.00 | Unspecified malignant neoplasm of skin of lip |
| 44.01 | Basal cell carcinoma of skin of lip |
| C44.02 | Squamous cell carcinoma of skin of lip |
| C44.09 | Other specified malignant neoplasm of skin of lip |
| C45.0 | Mesothelioma of pleura |
| C45.1 | Mesothelioma of peritoneum |
| C48.0 – C48.8 | Malignant neoplasm of retroperitoneum and peritoneum |
| C49.0 – C49.9 | Malignant neoplasm of other connective and soft tissue |
| C49.A0 – C49.A9 | Gastrointestinal stromal tumor |
| CS0.011 – CS0.929 | Malignant neoplasm of breast, female and male |
| C54.0 – C57.4 | Malignant neoplasm of corpus uteri, uterus, part unspecified, ovary, fallopian tube, broad ligament, round ligament, parametrium and uterine adnexa, unspecified |

| | |
|---|---|
| C61 | Malignant neoplasm of prostate |
| C63.7 | Malignant neoplasm of other specified male genital organs |
| C63.8 | Malignant neoplasm of overlapping sites of male genital organs |
| C65.0 – C67.9 | Malignant neoplasm of unspecified renal pelvis, ureter and bladder |
| C68.0 | Malignant neoplasm of urethra |
| C73 | Malignant neoplasm of thyroid gland |
| C76.0 | Malignant neoplasm of head, face and neck |
| C77.0 | Secondary and unspecified malignant neoplasm of lymph nodes of head, face<br>and neck |
| C78.00 – (78.02 | Secondary malignant neoplasm of lung |
| C79.31 | Secondary malignant neoplasm of brain |
| C79.51 | Secondary malignant neoplasm of bone |
| C79.52 | Secondary malignant neoplasm of bone marrow |
| C79.89 | Secondary malignant neoplasm of other specified sites |
| C79.9 | Secondary malignant neoplasm of unspecified site |
| C80.0 | Disseminated malignant neoplasm, unspecified |
| C80.1 | Malignant (primary) neoplasm, unspecified |
| D09.0 | Carcinoma in situ of bladder |
| D37.01 | Neoplasm of uncertain behavior of lip |
| D37.02 | Neoplasm of uncertain behavior of tongue |
| D37.030 – D37.039 | Neoplasm of uncertain behavior of the major salivary glands |
| D37.04 | Neoplasm of uncertain behavior of the minor salivary glands |
| D37.05 | Neoplasm of uncertain behavior of pharynx |
| D37.09 | Neoplasm of uncertain behavior of other specified sites of the oral cavity |
| D37.1 | Neoplasm of uncertain behavior of stomach |
| D37.2 | Neoplasm of uncertain behavior of small intestine |
| D37.3 | Neoplasm of uncertain behavior of appendix |
| D37.4 | Neoplasm of uncertain behavior of colon |
| D37.5 | Neoplasm of uncertain behavior of rectum |
| D37.8 | Neoplasm of uncertain behavior of other specified digestive organs |
| D37.9 | Neoplasm of uncertain behavior of digestive organ, unspecified |
| D38.0 | Neoplasm of uncertain behavior of larynx |
| D38.5 | Neoplasm of uncertain behavior of other respiratory organs |
| D38.6 | Neoplasm of uncertain behavior of respiratory organ, unspecified |
| D48.l | Neoplasm of uncertain behavior of connective and other soft tissue |
| D49.0 – D49.2 | Neoplasm of unspecified behavior of digestive system, respiratory system and<br>bone, soft tissue, and skin |
| D49.511 | Neoplasm of unspecified behavior of right kidney |
| D49.512 | Neoplasm of unspecified behavior of left kidney |
| D49.519 | Neoplasm of unspecified behavior of unspecified kidney |
| D49.59 | Neoplasm of unspecified behavior of other genitourinary organ |
| D49.6 | Neoplasm of unspecified behavior of brain |
| D49.81 – D49.9 | Neoplasm of unspecified behavior of retina and choroid, other specified sites and unspecified site |
| G73.1 | Lambert-Eaton syndrome |

| **Evenity** | |
|---|---|
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| M80.00XA – M80.00XS | Age-related osteoporosis with current pathological fracture |

| | |
|---|---|
| M80.011A – M80.011S<br>M80.012A – M80.012S<br>M80.019A – M80.019S<br>M80.021A – M80.021S<br>M80.022A – M80.022S<br>M80.029A – M80.029S<br>M80.031A – M80.031S<br>M80.032A – M80.032S<br>M80.039A – M80.039S<br>M80.041A – M80.041S<br>M80.042A – M80.042S<br>M80.049A – M80.049S<br>M80.051A – M80.051S<br>M80.052A – M80.052S<br>M80.059A – M80.059S<br>M80.061A – M80.061S<br>M80.062A – M80.062S<br>M80.069A – M80.069S<br>M80.071A – M80.071S<br>M80.072A – M80.072S | |

| **Evkeeza** | |
|---|---|
| E78.01 | Familial hypercholesterolemia |

| **Exdensur** | |
|---|---|
| D72.110- D72.119 | Hypereosinophilic syndrome [HES] |
| J32.0 - J32.9 | Chronic sinusitis [with nasal polyposis] |
| J33.0 – J33.9 | Nasal polyp |
| J44.0-J44.9 | Other chronic obstructive pulmonary disease |
| J82.83 | Eosinophilic asthma |
| M30.1 | Polyarteritis with lung involvement [Churg-Strauss] |

| **Fasenra** | |
|---|---|
| J82 | Pulmonary eosinophilia, not elsewhere classified |
| M30.1 | Polyarteritis with lung involvement [Churg-Strauss] |

| **Focinvez** | |
|---|---|
| Rll.0 | Nausea |
| Rll.10 – Rll.12 | Vomiting, unspecified |
| Rll.2 | Nausea with vomiting, unspecified |
| T45.1XSA | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter |
| T45.1XSD | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter |
| T45.1XSS | Adverse effect of antineoplastic and immunosuppressive drugs, sequela |
| T45.95XA | Adverse effect of unspecified primarily systemic and hematological agent, initial encounter |
| TS0.905A | Adverse effect of unspecified drugs, medicaments and biological substances |

| | |
|---|---|
| ZSl.11 | Encounter for antineoplastic chemotherapy |
| ZSl.12 | Encounter for antineoplastic immunotherapy |

| **Fusilev** | |
|---|---|
| C15.3 – C15.5<br>C15.8<br>C15.9 | Malignant neoplasm of esophagus |
| C16.0 – C16.9 | Malignant neoplasm of stomach |
| C17.0 – C17.3<br>C17.8<br>C17.9 | Malignant neoplasm of small intestine |
| C18.0 – C18.9 | Malignant neoplasm of the colon |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.0 – C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C25.0 – C25.4<br>C25.7 – C25.9 | Malignant neoplasm of pancreas |
| C37 | Malignant neoplasm of thymus |
| C40.00 – C40.02 | Malignant neoplasm of scapula and long bones of upper limb |
| C40.10 – C40.12 | Malignant neoplasm of short bones of upper limb |
| C40.20 – C40.22 | Malignant neoplasm of long bones of lower limb |
| C40.30 – C40.32 | Malignant neoplasm of short bones of lower limb |
| C40.80 – C40.82 | Malignant neoplasm of overlapping sites of bone and articular cartilage of limb |
| C40.90 – C40.92 | Malignant neoplasm of unspecified bones and articular cartilage of limb |
| C41.0 – C41.4<br>C41.9 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites |
| C48.1 – C48.8 | Malignant neoplasm of retroperitoneum and peritoneum |
| C53.0 – C53.9 | Malignant neoplasm of cervix uteri |
| C56.1 – C56.9 | Malignant neoplasm of ovary |
| C57.00 – C57.9 | Malignant neoplasm of other and unspecified female genital organs |
| C67.0 – C67.9 | Malignant neoplasm of bladder |
| C78.00 – C78.02 | Secondary malignant neoplasm of lung |
| C78.1 | Secondary malignant neoplasm of mediastinum |
| C78.2 | Secondary malignant neoplasm of pleura |
| C78.30, C78.39 | Secondary malignant neoplasm of other and unspecified respiratory organs |
| C78.4 | Secondary malignant neoplasm of small intestine |
| C78.5 | Secondary malignant neoplasm of large intestine and rectum |
| C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| C78.80, C78.89 | Secondary malignant neoplasm of other and unspecified digestive organs |
| C79.31, C79.32 | Secondary malignant neoplasm of brain and cerebral meninges |
| C79.40, C79.49 | Secondary malignant neoplasm of other and unspecified parts of nervous system |
| C79.89, C79.9 | Secondary malignant neoplasm of other specified and unspecified site |
| C80.0 | Disseminated malignant neoplasm, unspecified |
| C80.1 | Malignant (primary) neoplasm, unspecified |
| C83.00 – C83.09 | Small cell b-cell lymphoma |
| C83.10 – C83.19 | Mantle cell lymphoma |
| C83.30 – C83.39 | Diffuse large b-cell lymphoma |
| C83.50 – C83.59 | Lymphoblastic (diffuse) lymphoma |
| C83.70 – C83.79 | Burkitt lymphoma |
| C83.80 – C83.89 | Other non-follicular lymphoma |
| C83.90 – C83.99 | Non-follicular (diffuse) lymphoma, unspecified |

| | |
|---|---|
| C84.40 – C84.49 | Mature T/NK-cell lymphomas |
| C84.60 – C84.69 | Anaplastic large cell lymphoma, alk-positive |
| C84.70 – C84.79 | Anaplastic large cell lymphoma, alk-negative |
| C84.Z0 – C84.Z9 | Other mature T/NK-cell lymphomas |
| C84.90 – C84.99 | Mature T/NK-cell lymphomas, unspecified |
| C85.80 – C85.89 | Other specified types of non-hodgkin lymphoma |
| C86.0 – C86.6 | Other specified types of T/NK-cell lymphoma |
| C91.00 – C91.02 | Acute lymphoblastic leukemia [all] |
| C91.50 – C91.52 | Adult T-cell lymphoma/leukemia |
| C91.Z0 | Other lymphoid leukemia not having achieved remission |
| C91.Z2 | Other lymphoid leukemia, in relapse |
| D15.0 | Benign neoplasm of thymus |
| D37.1 – D37.9 | Neoplasm of uncertain behavior of oral cavity and digestive organs |
| T36.8X1A, t36.8X1D, T36.8X1S | Poisoning by other systemic antibiotics, accidental (unintentional) |
| T36.8X2A, T36.8X2D, T36.8X2S | Poisoning by other systemic antibiotics, intentional self-harm |
| T36.8X3A, T36.8X3D, T36.8X3S | Poisoning by other systemic antibiotics, assault |
| T36.8X4A, T36.8X4D, 36.8X4S | Poisoning by other systemic antibiotics, undetermined |
| T37.0X1A, T37.0X1D, T37.0X1S | Poisoning by sulfonamides, accidental (unintentional) |
| T37.0X2A, T37.0X2D, T37.0X2S | Poisoning by sulfonamides, intentional self-harm |
| T37.0X3A, T37.0X3D, T37.0X3S | Poisoning by sulfonamides, assault |
| T37.0X4A, T37.0X4D, T37.0X4S | Poisoning by sulfonamides, undetermined |
| T37.2X1A, T37.2X1D, T37.2X1S | Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional) |
| T37.2X2A, T37.2X2D T37.2X2S | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm |
| T37.2X3A, T37.2X3D, T37.2X3S | Poisoning by antimalarials and drugs acting on other blood protozoa, assault |
| T37.2X4A, T37.2X4D, T37.2X4S | Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined |
| T39.4X1A, T39.4X1D, T39.4X1S | Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional) |
| T39.4X2A, T39.4X2D, T39.4X2S | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm |
| T39.4X3A, T39.4X3D, T39.4X3S | Poisoning by antirheumatics, not elsewhere classified, assault |
| T39.4X4A, T39.4X4D, T39.4X4S | Poisoning by antirheumatics, not elsewhere classified, undetermined |
| T45.1X1A, T45.1X1D, T45.1X1S | Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional) |
| T45.1X2A, T45.1X2D, T45.1X2S | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm |
| T45.1X3A, T45.1X3D, T45.1X3S | Poisoning by antineoplastic and immunosuppressive drugs, assault |
| T45.1X4A, T45.1X4D, T45.1X4S | Poisoning by antineoplastic and immunosuppressive drugs, undetermined |
| T45.1X5A, T45.1X5D, | Adverse effect of antineoplastic and immunosuppressive drugs |

| | |
|---|---|
| T45.1X5S | |

| **Hemophilia Clotting Factors** | |
|---|---|
| D66 | Hereditary factor VIII deficiency |
| D67 | Hereditary factor IX deficiency |
| D68.0 | Von Willebrand's disease |
| D68.1 | Hereditary factor XI deficiency |
| D68.2 | Hereditary deficiency of other clotting factors |
| D68.31 | Hemorrhagic disorder due to intrinsic circulating anticoagulants |
| D68.32 | Hemorrhagic disorder due to extrinsic circulating anticoagulants |
| D68.4 | Acquired coagulation factor deficiency |
| D69.1 | Qualitative platelet defects |

| **Hemophilia Non-Clotting Factors (SC)** | |
|---|---|
| D66 | Hereditary factor VIII deficiency |
| D67 | Hereditary factor IX deficiency |

| **Imaavy** | |
|---|---|
| G70.00 | Myasthenia gravis without (acute) exacerbation |
| G70.01 | Myasthenia gravis with (acute) exacerbation |

| **Immune Globulins (IVIG, SCIG)** | |
|---|---|
| A48.3 | Toxic shock syndrome |
| B01.0 – B01.89 | Varicella |
| B05.0 – B05.89 | Measles |
| B06.0 – B06.89 | Rubella |
| B18.2 | Chronic viral hepatitis C |
| B20 | Human immunodeficiency virus [HIV] disease |
| B25.0 – B25.9 | Cytomegalovirus disease |
| B27.00 – B27.99 | Infectious mononeucleosis (Epstein Barr virus) |
| B34.3 | Parvovirus infection |
| B97.4 | Respiratory syncytial virus |
| C82 – C85.9 | Lymphomas (nonhodgkins) |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.01 | Multiple myeloma in remission |
| C90.02 | Multiple myeloma in relapse |
| C91.0 – C91.02 | Acute lymphoblastic leukemia |
| C91.10 | Chronic lymphocytic leukemia of B-cell type not having achieved remission |
| C91.11 | Chronic lymphocytic leukemia of B-cell type in remission |
| C91.12 | Chronic lymphocytic leukemia of B-cell type in relapse |
| C92.00 – C92.02<br>C92.40 – C92.42<br>C92.50 – C92.52<br>C92.60 – C92.62<br>C92.A0 – C92.A2 | Acute myeloblastic leukemia |
| C92.1 – C92.12 | Chronic myeloblastic leukemia |
| D59.0 | Drug-induced autoimmune hemolytic anemia |
| D59.1 | Other autoimmune hemolytic anemias |
| D59.11 | Warm autoimmune hemolytic anemia |
| D69.3 | Immune thrombocytopenic purpura |
| D69.41 | Evans syndrome |
| D69.42 | Congenital and hereditary thrombocytopenia purpura |

| | |
|---|---|
| D69.49 | Other primary thrombocytopenia |
| D69.51 | Posttransfusion purpura |
| D69.59 | Other secondary thrombocytopenia |
| D69.6 | Thrombocytopenia, unspecified |
| D80.0 | Hereditary hypogammaglobulinemia |
| D80.1 | Nonfamilial hypogammaglobulinemia |
| D80.3 | Selective deficiency of immunoglobulin G [IgG] subclasses |
| D80.4 | Selective deficiency of immunoglobulin M [IgM] |
| D80.5 | Immunodeficiency with increased immunoglobulin M [IgM] |
| D80.6 | Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia (Specific antibody deficiency) |
| D80.7 | Transient hypogammaglobulinemia of infancy |
| D80.8 | Other immunodeficiencies with predominant antibody defects |
| D80.9 | Immunodeficiency with predominantly antibody defects, unspecified |
| D81.0 | Severe combined immunodeficiency [SCID] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCID] with low T- and B-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCID] with low or normal B-cell numbers |
| D81.3 | Adenosine deaminase deficiency |
| D81.6 | Major histocompatibility complex class I deficiency |
| D81.7 | Major histocompatibility complex class II deficiency |
| D81.89 | Other combined immunodeficiencies |
| D81.9 | Combined immunodeficiency, unspecified |
| D82.0 | Wiskott-Aldrich syndrome |
| D82.1 | DiGeorge Syndrome |
| D82.3 | Immunodeficiency following hereditary defective response to Epstein-Barr virus |
| D82.4 | Hyperimmunoglobulin E (IgE) syndrome |
| D82.8 | Immunodeficiency associated with other specified major defects |
| D82.9 | Immunodeficiency associated with major defect, unspecified |
| D83.0 | Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function |
| D83.1 | Common variable immunodeficiency with prominent immunoregulatory T-cell disorder |
| D83.2 | Common variable immunodeficiency with autoantibodies to B- or T-cells |
| D83.8 | Other common variable immunodeficiencies |
| D83.9 | Common variable immunodeficiency, unspecified |
| D84.81 | Immunodeficiency due to conditions classified elsewhere |
| D84.821 | Immunodeficiency due to drugs |
| D84.89 | Other immunodeficiencies |
| D84.9 | Immunodeficiency unspecified |
| D89.810 | Acute graft-versus-host disease |
| D89.834 – D89.839 | Cytokine release syndrome |
| G04.00 – G04.02 | Acute disseminated encephalitis and encephalomyelitis |
| G04.81 | Other encephalitis and encephalomyelitis |
| G25.82 | Stiff-man syndrome |
| G60.3 | Idiopathic progressive neuropathy |
| G60.8 | Other hereditary and idiopathic neuropathies |
| G60.9 | Hereditary and idiopathic neuropathies, unspecified |
| G61.0 | Guillian-Barre syndrome |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |
| G61.82 | Multifocal motor neuropathy |
| G61.9 | Inflammatory polyneuropathy, unspecified |
| G62.89 | Other specified polyneuropathies |
| G70.00 | Myasthenia gravis without (acute) exacerbation |

| | |
|---|---|
| G70.01 | Myasthenia gravis with (acute) exacerbation |
| G70.80 | Lambert-Eaton syndrome, unspecified |
| G70.81 | Lambert-Eaton syndrome in disease classified elsewhere |
| J20.5 | Acute bronchitis due to RSV |
| L10.0 | Pemphigus vulgaris |
| L10.2 | Pemphigus foliaceous |
| L12.0 | Bullous pemphigoid |
| L12.1 | Cicatricial pemphigoid |
| L12.30 | Acquired epidermolysis bullosa, unspecified |
| L12.31 | Epidermolysis bullosa due to drug |
| L12.35 | Other acquired epidermolysis bullosa |
| L13.8 – L13.9 | Other specified bullous disorders |
| M30.3 | Mucocutaneous lymph node syndrome (Kawasaki) |
| M33.00 – M33.09 | Juvenile dermatopolymyositis, organ involvement |
| M33.20 – M33.29 | Polymyositis, organ involvement |
| M33.90 – M33.99 | Dermatopolymyositis, organ involvement unspecified |
| O98.511 – O98.519 | Other viral diseases complicating pregnancy |
| O98.713 | HIV disease complicating pregnancy |
| P07.00 – P07.30 | Disorders relating to short gestation and low birthweight code |
| P35.0 | Congenital rubella syndrome |
| P35.8 | Other congenital viral diseases |
| P35.9 | Congenital viral disease, unspecified |
| P55.0 – P55.1<br>P55.8 – P55.9 | Hemolytic disease or fetus or newborn due to isoimmunization |
| P61.0 | Transient neonatal thrombocytopenia |
| T45.1X5A T45.1X5D<br>T45.1X5S | Adverse effect of antineoplastic and immunosuppressive drugs |
| T86.00 – T86.99 | Complications of transplanted organs |
| Z20.4 | Contact with or exposure to rubella |
| Z20.820 | Contact or exposure to varicella |
| Z20.828 | Contact or exposure to other viral diseases |
| Z29.9 | Encounter for other prophylactic measures |
| Z41.8 | Prophylactic immunotherapy |

| **Infliximab products (Remicade, Inflectra, Renflexis, Avsola) (J1745, Q5103, Q5104, and Q5121)** | |
|---|---|
| D86.0 – D86.9 | Sarcoidosis |
| D89.810 | Acute graft-versus-host disease |
| D89.812 | Acute on chronic graft-versus-host disease |
| D89.831 – D89.839 | Cytokine release syndrome |
| H20.00 – H20.9 | Iridocyclitis |
| H44.111 – H44.119 | Panuveitis |
| H44.131 – H44.139 | Sympathetic uveitis |
| K31.6 | Fistula of stomach and duodenum |
| K50.00 – K50.919 | Crohn’s disease (regional enteritis) |
| K51.00 – K51.919 | Ulcerative colitis |
| K52.3 | Indeterminate colitis |
| K60.30 | Anal fistula, unspecified |
| K60.311 – K60.319 | Anal fistula, simple |
| K60.321 – K60.329 | Anal fistula, complex |
| K60.40 | Rectal fistula, unspecified |
| K60.411 – K60.419 | Rectal fistula, simple |
| K60.421 – K60.429 | Rectal fistula, complex |

| | |
|---|---|
| K60.50 | Anorectal fistula, unspecified |
| K60.511 – K60.519 | Anorectal fistula, simple |
| K60.521 – K60.529 | Anorectal fistula, complex |
| K63.2 | Fistula of intestine |
| L40.0 | Psoriasis vulgaris |
| L40.1 | Generalized pustular psoriasis |
| L40.3 | Pustulosis palmaris et plantaris |
| L40.50 – L40.59 | Arthropathic psoriasis |
| L40.8 | Other psoriasis [for erythrodermic psoriasis ONLY] |
| L73.2 | Hidradenitis suppurativa |
| M05.00 – M05.09 | Felty's syndrome |
| M05.10 – M05.19 | Rheumatoid lung disease with rheumatoid arthritis |
| M05.20 – M05.29 | Rheumatoid vasculitis with rheumatoid arthritis |
| M05.30 – M05.39 | Rheumatoid heart disease with rheumatoid arthritis |
| M05.40 – M05.49 | Rheumatoid myopathy with rheumatoid arthritis |
| M05.50 – M05.59 | Rheumatoid polyneuropathy with rheumatoid arthritis |
| M05.60 – M05.69 | Rheumatoid arthritis with involvement of other organs and systems |
| M05.70 – M05.79 | Rheumatoid arthritis with rheumatoid factor without organ or systems involvement |
| M05.80 – M05.89 | Other rheumatoid arthritis with rheumatoid factor |
| M05.9 | Rheumatoid arthritis with rheumatoid factor, unspecified |
| M06.00 – M06.09 | Rheumatoid arthritis without rheumatoid factor |
| M06.20 – M06.29 | Rheumatoid bursitis |
| M06.30 – M06.39 | Rheumatoid nodule |
| M06.4 | Inflammatory polyarthropathy |
| M06.80 – M06.89 | Other specified rheumatoid arthritis |
| M06.9 | Rheumatoid arthritis, unspecified |
| M08.00 – M08.09 | Unspecified Juvenile rheumatoid arthritis |
| M08.1 | Juvenile ankylosing spondylitis |
| M08.20 – M08.29 | Juvenile rheumatoid arthritis with systemic onset |
| M08.3 | Juvenile rheumatoid polyarthritis (seronegative) |
| M08.40 – M08.4A | Pauciarticular juvenile rheumatoid arthritis |
| M08.80 – M08.89 | Other juvenile arthritis |
| M08.80 – M08.99 | Juvenile arthritis, unspecified |
| M30.3 | Mucocutaneous lymph node syndrome [Kawasaki] |
| M31.30 – M31.31 | Wegener's granulomatosis |
| M31.4 | Aortic arch syndrome [Takayasu] |
| M35.2 | Behçet's disease |
| M35.81 | Multisystem inflammatory syndrome |
| M45.0 – M45.9 | Ankylosing spondylitis |
| M45.A0 – M45.AB | Non-radiographic axial spondyloarthritis |
| M46.81 – M46.89 | Other specified inflammatory spondylopathies |
| N82.2 | Fistula of vagina to small intestine |
| N82.3 | Fistula of vagina to large intestine |
| N82.4 | Other female intestinal-genital tract fistulae |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |

| **Infliximab-dyyb (Zymfentra) (J1748)** |
|---|

| | |
|---|---|
| K50.00 – K50.919 | Crohn's disease (regional enteritis) |
| K51.00 – K51.919 | Ulcerative colitis |

| **Injectafer** | |
|---|---|
| D50.0 | Iron deficiency anemia secondary to blood loss (chronic) |
| D50.1 | Sideropenic dysphagia |
| D50.8 | Other iron deficiency anemias |
| D50.9 | Iron deficiency anemia, unspecified |
| D63.0 | Anemia in neoplastic disease |
| D63.1 | Anemia in chronic kidney disease |
| D63.8 | Anemia in other chronic diseases classified elsewhere |
| D64.81 | Antineoplastic chemotherapy-induced anemia |

| **Izervay** | |
|---|---|
| H35.3113 | Advanced atrophic without subfoveal involvement, right eye |
| H35.3114 | Advanced atrophic with subfoveal involvement, right eye |
| H35.3123 | Advanced atrophic without subfoveal involvement, left eye |
| H35.3124 | Advanced atrophic with subfoveal involvement, left eye |
| H35.3133 | Advanced atrophic without subfoveal involvement, bilateral |
| H35.3134 | Advanced atrophic with subfoveal involvement, bilateral |
| H35.3113 | Advanced atrophic without subfoveal involvement, right eye |

| **Krystexxa** | |
|---|---|
| MlA.00X0 - M1A.09Xl | Idiopathic chronic gout |
| MlA.lOX0 - M1A.19Xl | Lead-induced chronic gout |
| M1A.20X0 - M1A.29Xl | Drug-induced chronic gout |
| M1A.30X0 - M1A.39Xl | Chronic gout due to renal impairment |
| M1A.40X0 - M1A.49Xl | Other secondary chronic gout |
| M1A.9XX0 - M1A.9XX1 | Chronic gout, unspecified |

| **Kyprolis** | |
|---|---|
| C88.00 | Waldenstrom macroglobulinemia not having achieved remission |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| C90.10 | Plasma cell leukemia not having achieved remission |
| C90.12 | Plasma cell leukemia in relapse |
| C90.20 | Extramedullary plasmacytoma not having achieved remission |
| C90.22 | Extramedullary plasmacytoma in relapse |
| C90.30 | Solitary plasmacytoma not having achieved remission |
| C90.32 | Solitary plasmacytoma in relapse |

| | |
|---|---|
| D47.2 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified [for POEMS syndrome only] |
| E85.3 | Secondary systemic amyloidosis |
| E85.4 | Organ-limited amyloidosis |
| E85.81 | Light chain (AL} amyloidosis |
| E85.89 | Other amyloidosis |
| E85.9 | Amyloidosis, unspecified |

| **Leqvio** | |
|---|---|
| E78.00 | Pure hypercholesterolemia, unspecified |
| E78.01 | Familial hypercholesterolemia |
| E78.2 | Mixed hyperlipidemia |
| E78.4 | Other hyperlipidemia |
| E78.49 | Other hyperlipidemia, familial combined hyperlipidemia |
| E78.5 | Hyperlipidemia, unspecified |
| E78.9 | Disorder of lipoprotein metabolism, unspecified |
| I20.2 | Refractory angina pectoris |
| I20.8 | Other forms of angina pectoris |
| I20.9 | Angina pectoris, unspecified |
| I21.01 – I21.A9 | Acute myocardial infarction |
| I22.0 – I22.9 | Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction |
| I23.7 | Postinfarction angina |
| I24.0 | Acute coronary thrombosis not resulting in myocardial infarction |
| I24.8 | Other forms of acute ischemic heart disease |
| I25.10 – I25.9 | Chronic ischemic heart disease |
| I63.00 – I63.9 | Cerebral infarction |
| I65.01 – I65.9 | Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction |
| I66.01 – I66.9 | Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction |
| I67.2 | Cerebral atherosclerosis |
| I67.81 | Acute cerebrovascular insufficiency |
| I67.82 | Cerebral ischemia |
| I67.89 | Other cerebrovascular disease |
| I67.9 | Cerebrovascular disease, unspecified |
| I68.8 | Other cerebrovascular disorders in diseases classified elsewhere |
| I70.0 – I70.92 | Atherosclerosis |
| I73.89 | Other specified peripheral vascular diseases |
| I73.9 | Peripheral vascular disease, unspecified |
| I74.01 – I74.9 | Arterial embolism and thrombosis |
| I75.011 – I75.89 | Atheroembolism |
| Z95.1 | Presence of aortocoronary bypass graft |
| Z95.5 | Presence of coronary angioplasty implant and graft |

| | |
|---|---|
| Z95.820 | Peripheral vascular angioplasty status with implants and grafts |
| Z98.61 | Coronary angioplasty status |
| Z98.62 | Peripheral vascular angioplasty status |

| **Macugen** | |
|---|---|
| E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
| E08.3211 – E08.3219 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema |
| E08.3311 – E08.3319 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema |
| E08.3411 – E08.3419 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema |
| E08.3511 – E08.3519 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema |
| E09.311 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E09.3211 – E09.3219 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E09.3311 – E09.3319 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E09.3411 – E09.3419 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E09.3511 – E09.3519 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E10.311 | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E10.3211 – E10.3219 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E10.3311 – E10.3319 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E10.3411 – E10.3419 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E10.3511 – E10.3519 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E11.311 | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E11.3211 – E11.3219 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E11.3311 – E11.3319 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E11.3411 – E11.3419 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E11.3511 – E11.3519 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E13.311 | Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E13.3211 – E13.3219 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E13.3311 – E13.3319 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E13.3411 – E13.3419 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |

| | |
|---|---|
| E13.3511 – E13.3519 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| H35.3210 – H35.3293 | Exudative age-related macular degeneration |

| **Monoferric** | |
|---|---|
| D50.0 | Iron deficiency anemia secondary to blood loss (chronic) |
| D50.1 | Sideropenic dysphagia |
| D50.8 | Other iron deficiency anemias |
| D50.9 | Iron deficiency anemia, unspecified |
| D63.0 | Anemia in neoplastic disease |
| D63.1 | Anemia in chronic kidney disease |
| D63.8 | Anemia in other chronic diseases classified elsewhere |
| D64.81 | Antineoplastic chemotherapy-induced anemia |

| **Nucala** | |
|---|---|
| D72.1 | Eosinophilia |
| J33.0-J33.9 | Nasal polyp |
| J82 | Pulmonary eosinophilia, not elsewhere classified |
| M30.1 | Polyarteritis with lung involvement [Churg-Strauss] |

| **Onivyde** | |
|---|---|
| C25.0- C25.9 | Malignant neoplasm of pancreas |
| C24.1 | Malignant neoplasm of ampulla of Vater |

| Orencia | |
|---|---|
| D89.810 – D89.813 | Graft-versus-host disease |
| L40.50 – L40.59 | Arthropathic psoriasis |
| M05.00 – M05.09 | Felty's syndrome |
| M05.10 – M05.19 | Rheumatoid lung disease with rheumatoid arthritis |
| M05.20 – M05.29 | Rheumatoid vasculitis with rheumatoid arthritis |
| M05.30 – M05.39 | Rheumatoid heart disease with rheumatoid arthritis |
| M05.40 – M05.49 | Rheumatoid myopathy with rheumatoid arthritis |
| M05.50 – M05.59 | Rheumatoid polyneuropathy with rheumatoid arthritis |
| M05.60 – M05.69 | Rheumatoid arthritis with involvement of other organs and systems |
| M05.70 – M05.7A | Rheumatoid arthritis with rheumatoid factor without organ or systems involvement |
| M05.80 – M05.8A | Other rheumatoid arthritis with rheumatoid factor |
| M05.9 | Rheumatoid arthritis with rheumatoid factor, unspecified |
| M05.A | Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis |
| M06.00 – M06.0A | Rheumatoid arthritis without rheumatoid factor |
| M06.20 – M06.29 | Rheumatoid bursitis |
| M06.30 – M06.39 | Rheumatoid nodule |
| M06.80 – M06.8A | Other specified rheumatoid arthritis |
| M06.9 | Rheumatoid arthritis, unspecified |
| M08.09 | Unspecified juvenile rheumatoid arthritis, multiple sites |
| M08.3 | Juvenile rheumatoid polyarthritis (seronegative) |
| M08.89 | Other juvenile arthritis, multiple sites |
| M31.5 | Giant cell arteritis with polymyalgia rheumatica |

| | |
|---|---|
| M31.6 | Other giant cell arteritis |
| M33.00 – M33.09 | Juvenile dermatopolymyositis |
| M33.10 – M33.19 | Other dermatopolymyositis |
| M33.20 – M33.29 | Polymyositis |
| M33.90 – M33.99 | Dermatopolymyositis, unspecified |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |

| Axtle, Pemfexy, Pemrydi RTU | |
|---|---|
| C33 | Malignant neoplasm of trachea |
| C34.00 | Malignant neoplasm of main bronchus, unspecified side |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.10 | Malignant neoplasm of upper lobe, bronchus or lung, unspecified side |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, right bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, bronchus or lung, unspecified side |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.80 | Malignant neoplasm of overlapping sites of bronchus and lung, unspecified side |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.90 | Malignant neoplasm of bronchus or lung, unspecified, unspecified side |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C37 | Malignant neoplasm of thymus |
| C38.4 | Malignant neoplasm of pleura |
| C45.0 | Mesothelioma of pleura |
| C45.1 | Mesothelioma of peritoneum |
| C45.2 | Mesothelioma of pericardium |
| C45.7 | Mesothelioma of other sites |
| C47.9 | Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C52 | Malignant neoplasm of vagina |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of ovary, unspecified side |
| C57.00 | Malignant neoplasm of fallopian tube, unspecified side |

| | |
|---|---|
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| C57.10 | Malignant neoplasm of broad ligament, unspecified side |
| C57.11 | Malignant neoplasm of right broad ligament |
| C57.12 | Malignant neoplasm of left broad ligament |
| C57.20 | Malignant neoplasm of round ligament, unspecified side |
| C57.21 | Malignant neoplasm of right round ligament |
| C57.22 | Malignant neoplasm of left round ligament |
| C57.3 | Malignant neoplasm of parametrium |
| C57.4 | Malignant neoplasm of uterine adnexa, unspecified |
| C57.7 | Malignant neoplasm of other specified female genital organs |
| C57.8 | Malignant neoplasm of overlapping sites of female genital organs |
| C57.9 | Malignant neoplasm of female genital organ, unspecified |
| C61 | Malignant neoplasm of prostate |
| C65.1 | Malignant neoplasm of right renal pelvis |
| C65.2 | Malignant neoplasm of left renal pelvis |
| C65.9 | Malignant neoplasm of renal pelvis, unspecified side |
| C66.1 | Malignant neoplasm of right ureter |
| C66.2 | Malignant neoplasm of left ureter |
| C66.9 | Malignant neoplasm of ureter, unspecified side |
| C67.0 | Malignant neoplasm of trigone of bladder |
| C67.1 | Malignant neoplasm of dome of bladder |
| C67.2 | Malignant neoplasm of lateral wall of bladder |
| C67.3 | Malignant neoplasm of anterior wall of bladder |
| C67.4 | Malignant neoplasm of posterior wall of bladder |
| C67.5 | Malignant neoplasm of bladder neck |
| C67.6 | Malignant neoplasm of ureteric orifice |
| C67.7 | Malignant neoplasm of urachus |
| C67.8 | Malignant neoplasm of overlapping sites of bladder |
| C67.9 | Malignant neoplasm of bladder, unspecified |
| C68.0 | Malignant neoplasm of urethra |
| C73 | Malignant neoplasm of the thyroid gland |
| C83.30 | Diffuse large B-cell lymphoma, unspecified site |
| C83.31 | Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck |
| C83.390 | Primary central nervous system lymphoma |
| C83.398 | Diffuse large B-cell lymphoma of other extranodal and solid organ sites |
| C83.80 | Other non-follicular lymphoma, unspecified site |
| C83.81 | Other non-follicular lymphoma, lymph nodes of head, face, and neck |
| C83.89 | Other non-follicular lymphoma, extranodal and solid organ sites |
| C85.89 | Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites |
| C85.99 | Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites |
| D09.0 | Carcinoma in situ of bladder |
| D15.0 | Benign neoplasm of thymus |

| **Posfrea** | |
|---|---|
| RII.0 | Nausea |
| RII.10 | Vomiting, unspecified |
| RII.11 | Vomiting without nausea |
| RII.12 | Projectile vomiting |
| RII.2 | Nausea with vomiting, unspecified |
| T45.1X5A | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter |
| T45.1X5D | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent |

| | |
|---|---|
| | encounter |
| T45.1X5S | Adverse effect of antineoplastic and immunosuppressive drugs, sequela |
| T45.95XA | Adverse effect of unspecified primarily systemic and hematological agent, initial encounter |
| T50.905A | Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter |
| T50.905S | Adverse effect of unspecified drugs, medicaments and biological substances, sequela |
| T66.xxxS | Radiation sickness, unspecified, sequela |
| ZSl.11 | Encounter for antineoplastic chemotherapy |
| ZSl.12 | Encounter for antineoplastic chemotherapy |

| **Prolia and its biosimilars** | |
|---|---|
| C50.011 – C50.929 | Malignant neoplasm of breast |
| C61 | Malignant neoplasm of prostate |
| C94.30 – C94.32 | Mast cell leukemia |
| C96.20 – C96.29 | Malignant mast cell neoplasm |
| D47.02 | Systemic mastocytosis |
| M80.00XA – M80.00XS<br>M80.011A – M80.011S<br>M80.012A – M80.012S<br>M80.019A – M80.019S<br>M80.021A – M80.021S<br>M80.022A – M80.022S<br>M80.029A – M80.029S<br>M80.031A – M80.031S<br>M80.032A – M80.032S<br>M80.039A – M80.039S<br>M80.041A – M80.041S<br>M80.042A – M80.042S<br>M80.049A – M80.049S<br>M80.051A – M80.051S<br>M80.052A – M80.052S<br>M80.059A – M80.059S<br>M80.061A – M80.061S<br>M80.062A – M80.062S<br>M80.069A – M80.069S<br>M80.071A – M80.071S<br>M80.072A – M80.072S<br>M80.079A – M80.079S<br>M80.08XA – M80.08XS<br>M80.0AXA – M80.0AXS<br>M80.0B1A – M80.0B1S<br>M80.0B2A – M80.0B2S<br>M80.0B9A – M80.0B9S | Age-related osteoporosis with current pathological fracture |
| M80.80XA – M80.80XS<br>M80.811A – M80.811S<br>M80.812A – M80.812S<br>M80.819A – M80.819S<br>M80.821A – M80.821S<br>M80.822A – M80.822S<br>M80.829A – M80.829S<br>M80.831A – M80.831S<br>M80.832A – M80.832S | Other osteoporosis with current pathological fracture |

| | |
|---|---|
| M80.839A – M80.839S<br>M80.841A – M80.841S<br>M80.842A – M80.842S<br>M80.849A – M80.849S<br>M80.851A – M80.851S<br>M80.852A – M80.852S<br>M80.859A – M80.859S<br>M80.861A – M80.861S<br>M80.862A – M80.862S<br>M80.869A – M80.869S<br>M80.871A – M80.871S<br>M80.872A – M80.872S<br>M80.879A – M80.879S<br>M80.88XA – M80.88XS<br>M80.8AXA – M80.8AXS<br>M80.8B1A – M80.8B1S<br>M80.8B2A – M80.8B2S<br>M80.8B9A – M80.8B9S | |
| M81.0 | Age-related osteoporosis without current pathological fracture |
| M81.6 | Localized osteoporosis (Lequesne) |
| M81.8 | Other osteoporosis without current pathological fracture |
| M89.9 | Disorder of bone, unspecified |
| M94.9 | Disorder of cartilage, unspecified |
| N95.1 | Menopausal and female climacteric states |
| T38.0X5A – T38.0X5S | Adverse effect of glucocorticoids and synthetic analogues |
| T38.6X5A – T38.6X5S | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified |
| T38.7X5A – T38.7X5S | Adverse effect of androgens and anabolic congeners |
| Z78.0 | Asymptomatic menopausal state |
| Z79.811 | Long term (current) use of aromatase inhibitors |
| Z79.818 | Long term (current) use of other agents affecting estrogen receptors and estrogen levels |

| **Rituxan** | |
|---|---|
| C82.00 – C82.99 | Follicular lymphoma, Grades I-IIIb, diffuse follicle center lymphoma, cutaneous follicle center lymphoma, other and unspecified |
| C83.80 – C83.89 | Other non-follicular lymphoma, lymph nodes of specific sites |
| C85.10 – C85.19 | Unspecified B-cell lymphoma |
| C85.90 – C85.99 | Non-Hodgkin's lymphoma, unspecified |
| C91.10 | Chronic lymphocytic leukemia of B-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of B-cell type in relapse |

| **Saphnelo** | |
|---|---|
| M32.10-M32.19 | Systemic lupus erythematosus with organ or system involvement |
| M32.8 | Other forms of systemic lupus erythematosus |
| M32.9 | Systemic lupus erythematosus, unspecified |

| **Soliris** | |
|---|---|
| D59.31 | Infection-associated hemolytic-uremic syndrome |
| D59.32 | Hereditary hemolytic-uremic syndrome |
| D59.39 | Other hemolytic-uremic syndrome |
| D59.5 | Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] |

| | |
|---|---|
| G36.0 | Neuromyelitis optica [Devic] |
| G70.00 | Myasthenia gravis without (acute) exacerbation |
| G70.01 | Myasthenia gravis with (acute) exacerbation |
| N00.6 | Acute nephritic syndrome with dense deposit disease |
| N01.6 | Rapidly progressive nephritic syndrome with dense deposit disease |
| N02.6 | Recurrent and persistent hematuria with dense deposit disease |
| N03.6 | Chronic nephritic syndrome with dense deposit disease |
| N04.6 | Nephrotic syndrome with dense deposit disease |
| N07.6 | Hereditary nephropathy, not elsewhere classified with dense deposit disease |
| T86.19 | Other complication of kidney transplant |

| **Stelara and injectable biosimilars (J3358, Q5098, Q5099, Q5100, Q5138, Q9997, Q9998, Q9999)** | |
|---|---|
| K50.00 – K50.919 | Crohn's disease [regional enteritis] |
| K51.00 – K51.919 | Ulcerative colitis |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |

| **Tocilizumab products (Actemra, Tofidence, Tyenne) (J3262, Q5133, Q5135)** | |
|---|---|
| B10.89 | Other human herpesvirus infection |
| D47.Z2 | Castleman disease |
| D89.810 | Acute graft-versus-host disease |
| D89.812 | Acute on chronic graft-versus-host disease |
| D89.832 | Cytokine release syndrome, grade 2 |
| D89.833 | Cytokine release syndrome, grade 3 |
| D89.834 | Cytokine release syndrome, grade 4 |
| D89.839 | Cytokine release syndrome, grade unspecified |
| G36.0 | Neuromyelitis optica [Devic] |
| G92.00 | Immune effector cell-associated neurotoxicity syndrome, grade unspecified |
| G92.01 | Immune effector cell-associated neurotoxicity syndrome, grade 1 |
| G92.02 | Immune effector cell-associated neurotoxicity syndrome, grade 2 |
| G92.03 | Immune effector cell-associated neurotoxicity syndrome, grade 3 |
| G92.04 | Immune effector cell-associated neurotoxicity syndrome, grade 4 |
| M05.00 – M05.09 | Felty's syndrome |
| M05.10 – M05.19 | Rheumatoid lung disease with rheumatoid arthritis |
| M05.20 – M05.29 | Rheumatoid vasculitis with rheumatoid arthritis |
| M05.30 – M05.39 | Rheumatoid heart disease with rheumatoid arthritis |
| M05.40 – M05.49 | Rheumatoid myopathy with rheumatoid arthritis |
| M05.50 – M05.59 | Rheumatoid polyneuropathy with rheumatoid arthritis |
| M05.60 – M05.69 | Rheumatoid arthritis with involvement of other organs and systems |
| M05.70 – M05.7A | Rheumatoid arthritis with rheumatoid factor without organ or systems involvement |
| M05.80 – M05.8A | Other rheumatoid arthritis with rheumatoid factor |
| M05.9 | Rheumatoid arthritis with rheumatoid factor, unspecified |
| M06.00 – M06.0A | Rheumatoid arthritis without rheumatoid factor |
| M06.20 – M06.29 | Rheumatoid bursitis |
| M06.30 – M06.39 | Rheumatoid nodule |
| M06.80 – M06.8A | Other specified rheumatoid arthritis |
| M06.9 | Rheumatoid arthritis, unspecified |
| M08.09 | Unspecified juvenile rheumatoid, multiple sites |

| | |
|---|---|
| M08.20 – M08.2A | Juvenile rheumatoid arthritis with systemic onset |
| M08.3 | Juvenile rheumatoid polyarthritis (seronegative) |
| M08.89 | Other juvenile arthritis, multiple sites |
| M31.5 | Giant cell arteritis with polymyalgia rheumatica |
| M31.6 | Other giant cell arteritis |
| M34.0 – M34.9 | Systemic sclerosis [scleroderma] |
| R59.0 – R59.9 | Enlarged lymph nodes |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |
| T80.82XA | Complication of immune effector cellular therapy, initial encounter |
| T80.82XS | Complication of immune effector cellular therapy, subsequent encounter |
| U07.1 | COVID-19 |

| **Trastuzumab products (Herceptin, Herceptin Hylecta, Hercessi, Ogivri) (J9355, J9356, Q5146, Q5113, Q5114)** | |
|---|---|
| C15.3 – C16.9 | Malignant neoplasm of esophagus and stomach |
| C17.0 – C17.2 | Malignant neoplasm of duodenum, jejunum, ileum |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine |
| C18.0-C21.8 | Malignant neoplasm of colon, rectosigmoid junction, rectum and anus and anal canal |
| C25.0 – C25.9 | Malignant neoplasm of pancreas |
| C50.011 – C50.929 | Malignant neoplasm of female and male breast |
| C54.0 – C54.9 | Malignant neoplasm of corpus uteri |
| C55 | Malignant neoplasm of uterus, part unspecified |
| C79.32 | Secondary malignant neoplasm of cerebral meninges |
| C78.00 – C78.02 | Secondary malignant neoplasm of unspecified lung |
| C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| D37.1 | Neoplasm of uncertain behavior of stomach |
| D37.8 | Neoplasm of uncertain behavior of other specified digestive organs |
| D37.9 | Neoplasm of uncertain behavior of digestive organ, unspecified |

| **Viscosupplements** | |
|---|---|
| M17.0 | Bilateral primary osteoarthritis of knee |
| M17.11 | Unilateral primary osteoarthritis, right knee |
| M17.12 | Unilateral primary osteoarthritis, left knee |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee |
| M17.4 | Other bilateral secondary osteoarthritis of knee |
| M17.5 | Other unilateral secondary osteoarthritis of knee |
| M17.9 | Osteoarthritis of knee, unspecified |
| M19.011 | Primary osteoarthritis, right shoulder |
| M19.012 | Primary osteoarthritis, left shoulder |
| M19.111 | Post-traumatic osteoarthritis, right shoulder |
| M19.112 | Post-traumatic osteoarthritis, left shoulder |
| M19.211 | Secondary osteoarthritis, right shoulder |
| M19.212 | Secondary osteoarthritis, left shoulder |
| M75.41 | Impingement syndrome of right shoulder |

| | |
|---|---|
| M75.42 | Impingement syndrome of left shoulder |

| **Visudyne** | |
|---|---|
| B39.4 | Histoplasmosis capsulate, unspecified |
| B39.5 | Histoplasmosis duboisii |
| B39.9 | Histoplasmosis, unspecified |
| H32 | Chorioretinal disorders in diseases classified elsewhere |
| H35.3210 – H35.3293 | Exudative age-related macular degeneration |
| H44.2A1 | Degenerative myopia with choroidal neovascularization, right eye |
| H44.2A2 | Degenerative myopia with choroidal neovascularization, left eye |
| H44.2A3 | Degenerative myopia with choroidal neovascularization, bilateral eye |
| H44.2A9 | Degenerative myopia with choroidal neovascularization, unspecified eye |

| **Vivimusta** | |
|---|---|
| B20 [in combination with C83.30 – C83.39, C83.80 – C83.89, C83.90 – C83.99, C85.80 – C85.89] | Human immunodeficiency virus [HIV] disease [for AIDS-related B-cell lymphoma when billed in combination with another applicable code] |
| C81.00 – C81.09 | Nodular lymphocyte predominant Hodgkin lymphoma |
| C81.10 – C81.19 | Nodular sclerosis classical Hodgkin lymphoma |
| C81.20 – C81.29 | Mixed cellularity classical Hodgkin lymphoma |
| C81.30 – C81.39 | Lymphocyte depleted classical Hodgkin lymphoma |
| C81.40 – C81.49 | Lymphocyte-rich classical Hodgkin lymphoma |
| C81.70 – C81.79 | Other classical Hodgkin lymphoma |
| C81.90 – C81.99 | Hodgkin lymphoma, unspecified |
| C82.00 – C82.09 | Follicular lymphoma grade I |
| C82.10 – C82.19 | Follicular lymphoma grade II |
| C82.20 – C82.29 | Follicular lymphoma grade III, unspecified |
| C82.30 – C82.39 | Follicular lymphoma grade IIIa |
| C82.40 – C82.49 | Follicular lymphoma grade IIIb |
| C82.50 – C82.59 | Diffuse follicle center lymphoma |
| C82.60 – C82.69 | Cutaneous follicle center lymphoma |
| C82.80 – C82.89 | Other types of follicular lymphoma |
| C82.90 – C82.99 | Follicular lymphoma, unspecified |
| C83.00 – C83.09 | Small cell B-cell lymphoma |
| C83.10 – C83.19 | Mantle Cell lymphoma |
| C83.30 – C83.398 | Diffuse large B-cell lymphoma |
| C83.50 – C83.59 | Lymphoblastic (diffuse) lymphoma |
| C83.80 – C83.89 | Other non-follicular lymphoma |
| C83.90 – C83.99 | Non-follicular (diffuse) lymphoma, unspecified |
| C84.00 – C84.09 | Mycosis fungoides |
| C84.10 – C84.19 | Sézary disease |
| C84.40 – C84.49 | Peripheral T-cell lymphoma, not elsewhere classified |
| C84.60 – C84.69 | Anaplastic large cell lymphoma, ALK-positive |
| C84.70 – C84.7A | Anaplastic large cell lymphoma, ALK-negative |
| C84.90 - C84.99 | Mature T/NK-cell lymphomas, unspecified |
| C84.Z0 – C84.Z9 | Other mature T/NK-cell lymphomas |
| C85.20 – C85.29 | Mediastinal (thymic) large B-cell lymphoma |
| C85.80 – C85.89 | Other specified types of non-Hodgkin lymphoma |
| C86.10 | Hepatosplenic T-cell lymphoma not having achieved remission |
| C86.20 | Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission |
| C86.50 | Angioimmunoblastic T-cell lymphoma not having achieved remission |

| | |
|---|---|
| C88.00 | Waldenström macroglobulinemia not having achieved remission |
| C88.40 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission |
| C88.80 | Other malignant immunoproliferative diseases not having achieved remission |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| C90.10 | Plasma cell leukemia not having achieved remission |
| C90.12 | Plasma cell leukemia in relapse |
| C90.20 | Extramedullary plasmacytoma not having achieved remission |
| C90.22 | Extramedullary plasmacytoma in relapse |
| C90.30 | Solitary plasmacytoma not having achieved remission |
| C90.32 | Solitary plasmacytoma in relapse |
| C91.10 | Chronic lymphocytic leukemia of B-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of B-cell type in relapse |
| C91.50 | Adult T-cell lymphoma/leukemia (HTLV-1-associated), not having achieved remission |
| C91.52 | Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse |
| D47.Z1 | Post-transplant lymphoproliferative disorder (PTLD) |
| D59.12 | Cold autoimmune hemolytic anemia |
| E85.81 | Light chain (AL) amyloidosis |
| E85.89 | Other amyloidosis |
| E85.9 | Amyloidosis, unspecified |
| Z94.81 | Bone marrow transplant status |

| **Vyvgart Hytrulo** | |
|---|---|
| G70.00 – G70.01 | Myasthenia gravis |
| G61.81 | Chronic inflammatory demyelinating polyneuritis |

| **Xgeva and its biosimilars** | |
|---|---|
| C33 | C33 Malignant neoplasm of trachea |
| C34.00 – C34.02 | C34.00–C34.02 Malignant neoplasm of unspecified main bronchus |
| C34.10 – C34.12 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.30 – C34.32 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.80 – C34.82 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.90 – C34.92 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C41.0 – C41.9 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites |
| C50.011 – C50.929 | Malignant neoplasm of breast |
| C61 | Malignant neoplasm of prostate |
| C64.1 – C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| C65.1 – C65.9 | Malignant neoplasm of unspecified renal pelvis |
| C73 | Malignant neoplasm of thyroid gland |
| C79.51 – C79.52 | Secondary malignant neoplasm of bone and bone marrow |
| C90.00 – C90.02 | Multiple myeloma |
| D48.0 | Neoplasm of uncertain behavior of bone and articular cartilage |
| E83.52 | Hypercalcemia |

| **Zilretta** | |
|---|---|
| M17.0 | Bilateral primary osteoarthritis of knee |
| M17.11 | Unilateral primary osteoarthritis, right knee |
| M17.12 | Unilateral primary osteoarthritis, left knee |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee |

| | |
|---|---|
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee |
| M17,4 | Other bilateral secondary osteoarthritis of knee |
| M17.5 | Other unilateral secondary osteoarthritis of knee |

## REIMBURSEMENT INFORMATION:

Refer to section entitled **POSITION STATEMENT**.

## RELATED GUIDELINES:

**Erythropoiesis Stimulating Agents, 09-J0000-31**

**Granulocyte Colony Stimulating Factors, 09-J0000-62**

**H.P. Acthar Gel (Repository corticotropin), 09-J1000-15**

**Levoleucovorin (Fusilev and Khapzory) IV, 09-J2000-31**

**Palonosetron Hydrochloride (Aloxi), 09-J0000-87**

**Vascular Endothelial Growth Factor Inhibitors for Ocular Neovascularization, 09-J1000-78**

**Bendamustine HCL(Treanda), 09-J2000-40**

**Denosumab, (Xgeva), 09-J1000-25**

**Verteprofin, (Visudyne), 09-J1000-72**

**Eculizumab (Soliris), 09-J1000-17**

**Inclisiran (Leqvio), 09-J4000-21**

**Carfilzomib (Kyprolis) Injection, 09-J1000-81**

**Docetaxel Products, 09-J0000-95**

**Pemetrexed (Alimta, Axtle, Pemfexy, Remrydi RTU) IV, 09-J1000-01**

**Pegloticase (Krystexxa), 09-J3000-29**

**Clotting Factors and Coagulant Blood Products, 09-J0000-34**

**Subcutaneous Prophylactic Therapy for Hemophilia (Non-Clotting Factor) 09-J5000-12**

**Drugs and Biologics without a Medical Coverage Guideline, 09-J0000-68**

**Summary of Evidence:**

The Step Therapy programs are evaluated based on a thorough review of the available clinical evidence and standards of care, including clinical trials, observational studies, and other relevant data. The program's step therapy protocol is designed to ensure that beneficiaries receive therapeutically effective for their condition, while managing utilization and promoting high-quality care.

## REFERENCES:


1. Centers for Medicare and Medicaid Services, Health Plan Management System (HPMS), MA_Step_Therapy_HPMS_Memo_8_7_18; available at http://www.cms.gov – last checked August 31, 2018, and found under Medicare > Health Plans > Health Plans – General Information > Downloads.
2. Centers for Medicare and Medicaid Services, Medicare Benefit Policy Manual, CMS Pub. 100-02, Chapter 15, Sec. 50 (Rev. 241, Feb. 2, 2018); available at http://www.cms.gov – last checked August

31, 2018, and found under Medicare > Regulations and Guidance > Manuals > Internet-Only Manuals (IOMs).

3. Local Coverage Determination (LCD). Centers for Medicare & Medicare Services. http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx.
4. National Coverage Determination (NCD). Centers for Medicare & Medicare Services. http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx.
5. U.S. Food & Drug Administration. FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/.
6. Skelly, A., Bezlyak, V., Liew, G., Kap, E., & Sagkriotis, A. (2019). Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision (Basel, Switzerland), 3(3), 41. https://doi.org/10.3390/vision3030041
7. Novartis Pharmaceuticals Corporation. (2024). IV dosing | COSENTYX® (secukinumab) | HCP. CosentyxHCP.com. Retrieved October 31, 2024 https://www.cosentyxhcp.com/rheumatology/dosing-and-experience/iv-dosing

## COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Policy Committee on 09/09/26.

## GUIDELINE UPDATE INFORMATION:

| | |
|---|---|
| 07/15/19 | New Medical Coverage Guideline. |
| 01/01/21 | Review and revision to guideline; consisting of updating position statement, HCPCS coding and ICD-10 codes. |
| 06/15/22 | Review and revision to guideline; consisting of updating position statement. |
| 08/01/22 | Review and revision to guideline. |
| 11/09/22 | Review and revision to guideline; updated drug tables format. |
| 01/01/23 | Review and revision to guideline, including addition of new ST programs. |
| 05/15/23 | Revision to guidelines, consisting of the addition of non-preferred drugs for ST programs: Alymsys, Vegzelma [oncology]; Fylnetra, Rolvedon, Stimufend [pegylated filgrastim-colony stimulating factor]; Releuko, Leukine [filgrastim/ sargramostim – colony stimulating factor]; Aranesp, Mircera [epoetin]; Susvimo [ophthalmic-VEGF]. |
| 01/01/24 | Review and revision to guideline, including addition of new ST programs. |
| 03/15/24 | Review and revision to guidelines, consisting of addition of non-preferred drugs for ST programs: Avzivi [oncology]; Ryzneuta [colony stimulating factors]. |
| 06/15/24 | Revision to guidelines, consisting of the addition of non-preferred drugs Prolia and Evenity. |
| 10/01/24 | Revision to guidelines, consisting of the addition of new ST programs and addition of PiaSky as a preferred complement inhibitor. New HCPCS and ICD-10 codes. |
| 01/01/25 | Review and revision to position statement and guidelines, addition of non-preferred drugs for ST programs: Hercessi, Herzuma, Ogivri [Oncology], Nypozi [Colony Stimulating Factors], Yimmugo [Immune Globulins], Pavblu [Ophthalmic Agents], PiaSky [Complement Inhibitors], remove shortage statement [Erythropoeisis Stimulating Agents], and addition of new ST programs: Asthma Therapy [Cinqair], Immune Globulin Antibody Agents [Vyvgart Hytrulo]; and additional programs to ST categories: Autoimmune Therapy [Actemra, Tofidence, Renflexis, Zymfentra]. |
| 05/01/2025 | Review and revision to guidelines, consisting of the addition of new ST program: Systemic Lupus Erythematosus (SLE) Agents [Saphnelo], addition of non-preferred drugs for ST programs: Synojoynt [Viscosupplements], Evkeeza [Cardiovascular/Cholesterol Lowering Agents], Soliris, Bkemv, Epysqli [Complement |

| | |
|---|---|
| | Inhibitors], Enzeevu, Ahzantive [Ophthalmic Agents] update HCPCS codes for Eylea/Eylea HD, Pavblu, Soliris, methylprednisolone, Belrapzo, Vyvgart Hytrulo, Mircera. |
| 07/15/2025 | Review and revision to guidelines, consisting of update to existing ST categories: non-preferred drug Izervay [Ophthalmic Agents], non-preferred Focinvez, Cinvanti, Posfrea [Cancer and Supportive Therapy], non-preferred Imaavy [Complement Inhibitors] and removal of ST program [Erythropoiesis Stimulating Agents]. |
| 9/15/2025 | Review and revision to guidelines, consisting of update to existing ST categories: non-preferred drug Avtozma [Autoimmune Therapy], non-preferred Jubbonti, Stoboclo, Conexxence, Prolia [Bone Remodeling Agents], non-preferred Wyost, Osenvelt, Bomyntra , Xgeva [Cancer and Supportive Therapy], non-preferred Opuviz, Yesafili [Ophthalmic Agents]. |
| 10/01/2025 | Review and revision to guidelines, consisting of update to existing ST category: non-preferred drug Ziextenzo [Colony Stimulating Factors]. |
| 01/01/2026 | Review and revision to guidelines consisting of update to existing ST categories: non-preferred Cortrophin [Anti-Inflammatory Agents], non-preferred Avsola and preferred Renflexis [Autoimmune Therapy], non-preferred Stelara IV, Imuldosa, Otulfi, Pyzchiva, Starjemza, Wezlana, Yesintek and preferred Ustekinumab-aekn, Selarsdi, Steqeyma [Autoimmune Therapy], non-preferred (1) Bildyos, non-preferred (2) Ospomyv, Bosaya, Enoby [Bone Remodeling Agents], non-preferred Ontruzant, preferred Ogivri and Trazimera [Cancer and Supportive Therapy], preferred Riabni [Cancer and Supportive Therapy], non-preferred (1) Bilprevda, non-preferred (2) [Cancer and Supportive Therapy], non-preferred Nyvepria and preferred Fylnetra [Colony Stimulating Factors], preferred Epysqli [Complement Inhibitors], non-preferred (1) Eydenzelt, non-preferred (2) Beovu and Susvimo [Ophthalmic Agents]. |
| 03/01/2026 | Review and revision to guidelines: [Cancer and Supportive Therapy] |
| 05/15/2026 | Review and revision to guidelines consisting of update to existing ST categories: non-preferred Exdensur [Asthma Therapy] non-preferred Orencia [Autoimmune Therapy], Axtle, Pemfexy, Pemrydi RTU, Avgemsi, Boruzu, Kyxata, Docivyx, Beizray, Tepylute, Kyprolis [Cancer and Supportive Therapy]. Addition of new ST categories for non-preferred Krystexxa [Gout Agents] and non-preferred Qfitlia, Hympavzi, Alhemo, Altuviiio, Hemlibra [Hemophilia A Agents]. |
| 07/15/2026 | Review and revision to guidelines consisting of update to existing ST categories: HCPCS code updates for Asthma Therapy and Bone Remodeling Agents; non-preferred Vykoura, Vivimusta [Cancer and Supportive Therapy], non-preferred Qivigy [Immune Globulins]. |
| 10/01/2026 | Review and revision to guidelines consisting of update to existing ST categories: preferred Avtozma, preferred Pyzchiva, non-preferred Selarsdi [Autoimmune Therapy], non-preferred (1) Enoby and non-preferred (2) Jubbonti, , Boncresa, Osvyrti and Ponlimsi [Bone Remodeling Agents], preferred and non-preferred leucovorin, preferred docetaxel, non-preferred (1) Xtrenbo, non-preferred (2) Wyost, Oziltus, Osvryti, Jubereq [Cancer and Supportive Therapy], preferred Uplizna for gMG [Complement Inhibitors], non-prefered (1) Nufymco [Ophthalmic Agents]. |